Copyright
©The Author(s) 2017.
World J Gastrointest Surg. Feb 27, 2017; 9(2): 61-67
Published online Feb 27, 2017. doi: 10.4240/wjgs.v9.i2.61
Published online Feb 27, 2017. doi: 10.4240/wjgs.v9.i2.61
Table 1 Patient demographics
| FL-HCC (n = 22) | |
| Median age, years (range) | 29 yr (21 to 58) |
| Male/female | 11/11 (50%:50%) |
| Hepatitis or cirrhosis | 2 (9%) |
| Elevated AFP (> 200 ng/mL) | 2 (9%) |
Table 2 Tumor characteristics’ and treatment features n (%)
| FL-HCC (n = 22 ) | |
| Number | |
| Single | 19 (86) |
| Multiple | 3 (14) |
| Size (cm) | Median 12 cm (range, 5-20 ) |
| Location | 9 right, 10 left, 3 bilateral |
| Hepatic resection | |
| Hepatectomy | 16 (73) |
| Extended hepatectomy | 4 (18) |
| Localized resection | 2 (9) |
| Stage | |
| I | 10 (45) |
| II | 5 (23) |
| III | 7 (32) |
| IV | 0 |
| Nodal metastases | 4 (18) |
| Vascular invasion | 5 (23) |
| Positive safety margin | 2 (9) |
| Repeated hepatectomy | 4 (18) |
Table 3 Clinicopathologic features and survival in fibrolamellar carcinoma (figures in parenthesis reflect percentages)
| Factor | n (%) | Overall survival (mo) | P value |
| Age (yr) | |||
| < 40 | 16 (73) | 86 | |
| ≥ 40 | 6 (27) | 72 | 0.4 |
| Gender | |||
| Female | 11 (50) | 84 | |
| Male | 11 (50) | 79 | 0.6 |
| Tumor size (cm) | |||
| < 10 | 8 (36) | 82 | |
| ≥ 10 | 14 (64) | 76 | 0.3 |
| Number | |||
| 1 | 19 (86) | 89 | |
| > 1 | 3 (14) | 77 | 0.2 |
| Hepatic resection | |||
| Hepatectomy | 16 (73) | 86 | |
| Extended hepatectomy | 4 (18) | 77 | |
| Localized resection | 2 (9) | 79 | 0.62 |
| Nodal metastases | |||
| Negative | 18 (82) | 88 | |
| Positive | 4 (18) | 78 | 0.09 |
| Vascular invasion | |||
| Absent | 17 (77) | 92 | |
| Present | 5 (23) | 58 | 0.03 |
| Safety margin | |||
| Negative | 20 (91) | 87 | |
| Positive | 2 (9) | 72 | 0.08 |
Table 4 Published series on fibrolamellar hepatocellular carcinoma
| Ref. | n | Age | Male:female | Cirrhosis/ hepatitis | AFP elevated | Median size (cm) | > 1 tumor | Positive node | Vascular invasion | Initial operation | Repeat operation | Median f/u | 5 yr survival | Prognostic factor |
| Hemming et al[18], 1997 | 10 | 31 | 50:50 | NR | 10% | 8 | 20% | 20% | NR | Phx 100% | 50% | 101 | 70% | NR |
| El-Gazzaz et al[19], 2000 | 20 | 27 | 65:35 | 0% hep B | 0% | 14 | 20% | 30% | 55% | Phx 55% OLT 45% | NR | 25 | 50% | NONE |
| Kakar et al[20], 2005 | 20 | 27 | 53:27 | 0% | 3/13 (23%) | < 10 31% ≥ 10 69% | 10% | 35% | NR | Phx 100% | NR | NR | 62% | Metastasis at presentation |
| Stipa et al[21], 2006 | 28 | 28 | 43:57 | 0% | 7% | 9 | 11% | 50% | 36% | Phx 100% | 61% | 34 | 76% | Positive LN |
| Present study | 22 | 29 | 50:50 | 9%/hepc | 9% | 12 | 13% | 18% | 23% | Phx 100% | 18% | 42 | 65% | Vascular invasiom |
- Citation: Wahab MA, El Hanafy E, El Nakeeb A, Ali MA. Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). World J Gastrointest Surg 2017; 9(2): 61-67
- URL: https://www.wjgnet.com/1948-9366/full/v9/i2/61.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v9.i2.61
